For treatment in preclinical models of stroke or PD in the mouse, an 8D3-derived TfRMAb–TNFR fusion protein was engineered and expressed, and this fusion protein retained high affinity binding to both the mouse TfR1 and TNFα [783]. Here, TFRC is linked to Parkinson disease.